Katherine A Baugh1,2, Ifigeneia Tzannou1, Ann M Leen1. 1. Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital. 2. Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas, USA.
Abstract
PURPOSE OF REVIEW: Allogeneic hematopoietic stem cell transplantation has proven curative for a range of malignant and nonmalignant disorders. However, the clinical success of this therapy is marred by the morbidity associated with viral infections, which are frequent (cytomegalovirus 15.6-28%, adenovirus 3-21%, BK virus 18.5-20.7%) post-transplant. These infections occur as a consequence of transplant conditioning regimens designed to eliminate not only malignant cells but also host immune cells that might interfere with stem cell engraftment. The result is a transient period of immune compromise when hematopoietic stem cell transplant recipients are at risk of infectious complications associated with both latent (cytomegalovirus, Epstein-Barr virus, BK virus, human herpes virus 6, herpes simplex virus, varicella-zoster virus) and community-acquired viruses including adenovirus, respiratory syncytial virus, and parainfluenza virus. RECENT FINDINGS: Current standard of care for many of these infections involves pharmacologic agents, which are often ineffective and associated with side effects including nephrotoxicity and hepatotoxicity. Ultimately, because these agents do not address the underlying immune compromise, viral rebound often occurs. Thus, a number of groups have explored the clinical potential of adoptively transferred virus-specific T cells (VSTs) as an approach to prevent/treat virus-associated complications. SUMMARY: The current review will highlight recent publications showcasing VST manufacturing technologies and clinical experience with such cells.
PURPOSE OF REVIEW: Allogeneic hematopoietic stem cell transplantation has proven curative for a range of malignant and nonmalignant disorders. However, the clinical success of this therapy is marred by the morbidity associated with viral infections, which are frequent (cytomegalovirus 15.6-28%, adenovirus 3-21%, BK virus 18.5-20.7%) post-transplant. These infections occur as a consequence of transplant conditioning regimens designed to eliminate not only malignant cells but also host immune cells that might interfere with stem cell engraftment. The result is a transient period of immune compromise when hematopoietic stem cell transplant recipients are at risk of infectious complications associated with both latent (cytomegalovirus, Epstein-Barr virus, BK virus, human herpes virus 6, herpes simplex virus, varicella-zoster virus) and community-acquired viruses including adenovirus, respiratory syncytial virus, and parainfluenza virus. RECENT FINDINGS: Current standard of care for many of these infections involves pharmacologic agents, which are often ineffective and associated with side effects including nephrotoxicity and hepatotoxicity. Ultimately, because these agents do not address the underlying immune compromise, viral rebound often occurs. Thus, a number of groups have explored the clinical potential of adoptively transferred virus-specific T cells (VSTs) as an approach to prevent/treat virus-associated complications. SUMMARY: The current review will highlight recent publications showcasing VST manufacturing technologies and clinical experience with such cells.
Authors: Judith Feucht; Kathrin Opherk; Peter Lang; Simone Kayser; Lena Hartl; Wolfgang Bethge; Susanne Matthes-Martin; Peter Bader; Michael H Albert; Britta Maecker-Kolhoff; Johann Greil; Hermann Einsele; Paul-Gerhardt Schlegel; Friedhelm R Schuster; Bernhard Kremens; Claudia Rossig; Bernd Gruhn; Rupert Handgretinger; Tobias Feuchtinger Journal: Blood Date: 2015-01-23 Impact factor: 22.113
Authors: Tobias Feuchtinger; Kathrin Opherk; Wolfgang A Bethge; Max S Topp; Friedhelm R Schuster; Eva M Weissinger; Mohamad Mohty; Reuven Or; Michael Maschan; Michael Schumm; Klaus Hamprecht; Rupert Handgretinger; Peter Lang; Hermann Einsele Journal: Blood Date: 2010-07-12 Impact factor: 22.113
Authors: Ekaterina Doubrovina; Banu Oflaz-Sozmen; Susan E Prockop; Nancy A Kernan; Sara Abramson; Julie Teruya-Feldstein; Cyrus Hedvat; Joanne F Chou; Glenn Heller; Juliet N Barker; Farid Boulad; Hugo Castro-Malaspina; Diane George; Ann Jakubowski; Guenther Koehne; Esperanza B Papadopoulos; Andromachi Scaradavou; Trudy N Small; Ramzi Khalaf; James W Young; Richard J O'Reilly Journal: Blood Date: 2011-12-02 Impact factor: 22.113
Authors: S Shiobara; S Nakao; M Ueda; H Yamazaki; S Takahashi; S Asano; H Yabe; S Kato; S Imoto; A Maruta; T Yoshida; H Gondo; Y Morishima; Y Kodera Journal: Ther Apher Date: 2001-02
Authors: Karl S Peggs; Kirsty Thomson; Edward Samuel; Gemma Dyer; Julie Armoogum; Ronjon Chakraverty; Kwok Pang; Stephen Mackinnon; Mark W Lowdell Journal: Clin Infect Dis Date: 2011-01-01 Impact factor: 9.079
Authors: Lauren P McLaughlin; Haili Lang; Elizabeth Williams; Kaylor E Wright; Allison Powell; Conrad R Cruz; Anamaris M Colberg-Poley; Cecilia Barese; Patrick J Hanley; Catherine M Bollard; Michael D Keller Journal: Cytotherapy Date: 2016-09-28 Impact factor: 5.414
Authors: Ann M Leen; Anne Christin; Gary D Myers; Hao Liu; Conrad R Cruz; Patrick J Hanley; Alana A Kennedy-Nasser; Kathryn S Leung; Adrian P Gee; Robert A Krance; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney; Catherine M Bollard Journal: Blood Date: 2009-08-21 Impact factor: 22.113
Authors: Mark Cobbold; Naeem Khan; Batoul Pourgheysari; Sudhir Tauro; Dorothy McDonald; Husam Osman; Mario Assenmacher; Lucinda Billingham; Colin Steward; Charles Crawley; Eduardo Olavarria; John Goldman; Ronjon Chakraverty; Premini Mahendra; Charles Craddock; Paul A H Moss Journal: J Exp Med Date: 2005-08-01 Impact factor: 14.307
Authors: Jeremy D Rubinstein; Xiang Zhu; Carolyn Lutzko; Tom Leemhuis; Jose A Cancelas; Sonata Jodele; Catherine M Bollard; Patrick J Hanley; Stella M Davies; Michael S Grimley; Adam S Nelson Journal: Blood Adv Date: 2020-07-28
Authors: Jeremy D Rubinstein; Xiang Zhu; Thomas Leemhuis; Giang Pham; Lorraine Ray; Sana Emberesh; Sonata Jodele; Shawn Thomas; Jose A Cancelas; Catherine M Bollard; Patrick J Hanley; Michael D Keller; Olivia Grimley; Diana Clark; Teri Clark; Cecilia S Lindestam Arlehamn; Alessandro Sette; Stella M Davies; Adam S Nelson; Michael S Grimley; Carolyn Lutzko Journal: Blood Adv Date: 2021-09-14
Authors: Diego R Hijano; Jessica Brazelton de Cardenas; Gabriela Maron; Cherilyn D Garner; Jose A Ferrolino; Ronald H Dallas; Zhengming Gu; Randall T Hayden Journal: PLoS One Date: 2019-09-03 Impact factor: 3.240
Authors: Jeremy D Rubinstein; Carolyn Lutzko; Thomas Leemhuis; Xiang Zhu; Giang Pham; Lorraine Ray; Shawn Thomas; Celeste Dourson; Jamie Wilhelm; Adam Lane; Jose A Cancelas; Dakota Lipps; Justin Ferrell; Patrick J Hanley; Michael D Keller; Catherine M Bollard; YunZu M Wang; Stella M Davies; Adam S Nelson; Michael S Grimley Journal: Blood Adv Date: 2022-05-10